

Corimmun Has Received Funding within the “m4 – Personalized Medicine” Cluster Initiative

Martinsried/Munich, Germany, July 05, 2010 -- Corimmun GmbH, a privately held biopharmaceutical company developing novel therapeutics for the treatment of cardiovascular diseases, today announces that it has been awarded research funding from the federal program cluster initiative "m4" by the German Federal Ministry of Education (BMBF), which is managed by DLR, Bonn, Germany. The grant covers an R&D program of EUR 1.62 million to develop COR-1 in further Clinical Studies. A first clinical study in patients will be carried out at the Großhadern Clinic of the Ludwig-Maximilian University, Munich, Germany and at further large clinical entities.

"We are very pleased about the funding," commented Götz Münch, CEO of Corimmun. "It will enable us to further develop COR-1 as a drug for the personalized therapy of heart failure. We were happy that the approved application made part of the first round of “lighthouse” projects which were among the very first projects to be granted."

Notes to Editors

About M4 and the BMBF Cluster Initiative:

"Personalized medicine" offers the potential to overcome the current limitations in drug development. Individual variations between patients result in markedly different treatment successes or failures. This lack should be increasingly overcome by personalized medicine which offers the promise to develop "specifically tailored therapies".

Additional information: www.m4.de and www.spitzencluster.de

About COR-1:

Corimmun's lead product COR-1 is a cyclic peptide. It targets autoantibodies directed against the human β 1-adrenergic receptor. As a result, these auto-antibodies are inactivated and cardiac performance improves.

COR-1 has been validated in relevant animal models and has shown strong efficacy in terms of decrease of immune reaction and improvement of heart failure (clinical symptoms as well as hemodynamic parameters).

A recent Phase I clinical trial showed that COR-1 was well tolerated, no drug-related side effects occurred. Pharmacokinetics revealed a favourable profile with an almost complete serum clearance within 60 minutes after administration. Pharmacodynamic investigation showed dose-dependent efficacy with almost complete scavenging of pathological anti- β 1 receptor antibodies at the two highest doses.

About Corimmun

Corimmun GmbH (www.corimmun.com) is a private biotechnology company located in Martinsried near Munich, Germany, which focuses on cardiovascular diseases with unmet medical need. For these indications, Corimmun currently develops various projects in preclinical and clinical stage. The company receives constant scientific support from the outstanding university groups of the company's founders. In 2008, Corimmun successfully closed its Series A financing round, led by MIG Funds (www.mig.ag) with KfW, Bayern Kapital, High-Tech Fonds and Bio-M AG as Co-Investors.

Contact

Dr. Götz Münch, CEO Corimmun GmbH
Tel: +49-89-8565 2010
Email: muench@corimmun.com